Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk

Eur J Prev Cardiol. 2020 Mar;27(5):556-558. doi: 10.1177/2047487319839179. Epub 2019 Mar 26.

Authors

Arturo Cesaro^{1

2}, Felice Gragnano^{1

2}, Fabio Fimiani³, Elisabetta Moscarella^{1

2}, Vincenzo Diana^{1

2}, Ivana Pariggiano^{1

2}, Claudia Concilio^{1

2}, Francesco Natale³, Giuseppe Limongelli³, Eduardo Bossone⁴, Paolo Calabrò^{1

2}

Affiliations

¹ Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, Italy.
² Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
³ Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Monaldi Hospital, Naples, Italy.
⁴ Cardiology Division, A. Cardarelli Hospital, Naples, Italy.

PMID: 30913901
DOI: 10.1177/2047487319839179

No abstract available

Publication types

Letter

MeSH terms

Activities of Daily Living
Aged
Anticholesteremic Agents / therapeutic use*
Biomarkers / blood
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Cholesterol, LDL / blood*
Drug Therapy, Combination
Female
Health Status
Heart Disease Risk Factors
Humans
Hypercholesterolemia / blood
Hypercholesterolemia / complications
Hypercholesterolemia / diagnosis
Hypercholesterolemia / drug therapy*
Male
Mental Health
Middle Aged
PCSK9 Inhibitors*
Prospective Studies
Quality of Life*
Risk Assessment
Serine Proteinase Inhibitors / adverse effects
Serine Proteinase Inhibitors / therapeutic use*
Surveys and Questionnaires
Treatment Outcome

Substances

Anticholesteremic Agents
Biomarkers
Cholesterol, LDL
PCSK9 Inhibitors
Serine Proteinase Inhibitors
PCSK9 protein, human